Transitional cell carcinoma urethra – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:33:27 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Transitional cell carcinoma urethra – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-xl092-with-nivolumab-ipilimumab-and-relatlimab-for-patients-with-advanced-solid-tumors/ Wed, 29 Apr 2026 14:30:37 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-xl092-with-nivolumab-ipilimumab-and-relatlimab-for-patients-with-advanced-solid-tumors/ This clinical trial is focused on studying the effects of a new treatment for various types of advanced or metastatic solid tumors, which are cancers that have spread to other parts of the body and cannot be removed by surgery. The diseases being studied include clear cell renal cell carcinoma, metastatic castration-resistant prostate cancer, urothelial carcinoma, non-clear cell renal cell carcinoma, colorectal cancer, hepatocellular cancer, non-small cell lung cancer, and head and neck squamous cell carcinoma. The study will test a combination of medications, including zanzalintinib, nivolumab, ipilimumab, and relatlimab. These medications are designed to work together to help the immune system fight cancer.

The purpose of the study is to find the best dose of these medications and to see how safe and effective they are when used together. Participants will receive the medications in different combinations, either as a single treatment or in pairs or triplets. The study will also look at how the body processes these medications and how they affect cancer cells. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

During the study, participants will receive the treatment over a period of time, and their health will be closely monitored by the research team. The study will help determine the safety and potential benefits of these treatments for people with advanced cancers. The information gathered will contribute to understanding how these medications can be used to treat different types of cancer effectively.

]]> Study on Enfortumab Vedotin and Pembrolizumab for Patients with Advanced Urothelial Cancer https://clinicaltrials.eu/trial/study-on-enfortumab-vedotin-and-pembrolizumab-for-patients-with-advanced-urothelial-cancer/ Wed, 29 Apr 2026 14:26:44 +0000 https://clinicaltrials.eu/trial/study-on-enfortumab-vedotin-and-pembrolizumab-for-patients-with-advanced-urothelial-cancer/ This clinical trial is focused on studying the treatment of urothelial cancer, a type of cancer that occurs in the urinary system, including the bladder. The study is investigating the use of a medication called enfortumab vedotin, which is being tested both as a standalone treatment and in combination with other cancer therapies. One of the combinations being explored includes pembrolizumab, a medication that helps the immune system fight cancer. The purpose of the study is to assess the safety and effectiveness of these treatments in patients with urothelial cancer.

Participants in the study will receive the treatments through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will monitor how well the treatments work in reducing the size of the cancer and how safe they are for patients. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

The study will take place over a period of time, during which participants will have regular check-ups and assessments to track their progress. The goal is to gather information on how these treatments can help manage urothelial cancer and improve patient outcomes. This research is important for developing new and effective ways to treat this type of cancer.

]]> Study of Enfortumab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer https://clinicaltrials.eu/trial/study-of-enfortumab-vedotin-and-pembrolizumab-for-patients-with-advanced-or-metastatic-urothelial-cancer/ Wed, 29 Apr 2026 14:26:12 +0000 https://clinicaltrials.eu/trial/study-of-enfortumab-vedotin-and-pembrolizumab-for-patients-with-advanced-or-metastatic-urothelial-cancer/ This clinical trial is focused on studying treatments for urothelial cancer, a type of cancer that affects the bladder and other parts of the urinary system. The study is comparing two different treatment approaches. One group of participants will receive a combination of two medications: enfortumab vedotin and pembrolizumab. Pembrolizumab is also known by its code name, MK-3475. The other group will receive standard chemotherapy, which may include medications like gemcitabine, cisplatin, or carboplatin. These treatments are given as solutions through an infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of the study is to compare the effectiveness of the combination treatment with the standard chemotherapy in people who have not received prior treatment for their advanced or metastatic urothelial cancer. Participants will be randomly assigned to one of the two treatment groups. The study will monitor the participants over a period of time to see how well the cancer responds to the treatments and to assess overall survival rates.

Throughout the study, participants will receive regular medical check-ups and monitoring to ensure their safety and to track the progress of their treatment. The study aims to provide valuable information on whether the combination of enfortumab vedotin and pembrolizumab offers better outcomes compared to the standard chemotherapy options for patients with this type of cancer.

]]> Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with Advanced Unresectable Urothelial Cancer https://clinicaltrials.eu/trial/study-comparing-sacituzumab-govitecan-with-other-treatments-for-patients-with-advanced-unresectable-urothelial-cancer/ Wed, 29 Apr 2026 14:22:33 +0000 https://clinicaltrials.eu/trial/study-comparing-sacituzumab-govitecan-with-other-treatments-for-patients-with-advanced-unresectable-urothelial-cancer/ This clinical trial is focused on studying a type of cancer known as urothelial cancer, which affects the urinary system and can be either locally advanced or metastatic, meaning it has spread to other parts of the body. The study is comparing the effectiveness of a medication called sacituzumab govitecan with other treatments chosen by doctors. Sacituzumab govitecan is a type of medication known as an antibody-drug conjugate, which is designed to target and kill cancer cells.

The purpose of the study is to see how well sacituzumab govitecan works in helping patients live longer compared to other treatments. Participants in the study will receive either sacituzumab govitecan or a treatment selected by their doctor, which could include medications like docetaxel, vinflunine, or paclitaxel. These treatments are given as solutions for infusion, meaning they are administered directly into the bloodstream through a vein.

The study will follow participants over a period of time to monitor their health and the effects of the treatments. The goal is to gather information on how these treatments impact overall survival and other health outcomes in patients with advanced urothelial cancer. This information will help doctors understand which treatments may be most effective for this type of cancer.

]]>